ClinicalTrials.gg
RecruitingNCT06784908HIV StressUpdated Apr 27, 2026

Stress and Pain in People Living With HIV

An interventional study of Yale Pain Stress Task (YPST) in HIV, Depression and Cannabis Use Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 68 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Yale University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 68 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Depression by Yale University — 8 open to participants now, 9 under way, 1 of them phase 3. Depression · Yale University.

Planned enrollment
15th of 52
120 · median 51
Started
2025
with 1 other
No phase
35 of 60
4 open now
Registered
57th of 60
by date

Among the 60 studies in Depression by Yale University, this one is the 15th largest by planned enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2025, is one of 35 with no phase, and was the 57th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

8 of the 60 studies in Depression by Yale University are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 68 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Depression by Yale University, or all of them as a file.
02

Study summary

This is a basic human experimental study utilizing 4 groups of individuals with and without HIV and complex morbidities of cannabis use disorder and major depression who will participate in 2 sessions of the Yale Pain Stress Task (YPST) and follow-up phase to assess drug use and mood symptoms.

Read the detailed description

This study aims to address research gaps using a powerful and novel cross-diagnostic approach with multiple complementary approaches to examine the overarching hypothesis that PLWH+CM exhibit impaired stress-related HPA and HPA-immune function due to alterations in epigenetic mechanisms, and these stress-related HPA-immune and related epigenetic aberrations predict distress, craving and substance use symptoms underlying PLWH complex morbidities. This hypothesis will be tested using a combined human experimental stress challenge approach with prospective longitudinal assessment of daily distress, and substance use symptoms as well as assessment of chronic stress (C-stress), social determinants of health (SDoH), and resilience in experimental cohorts of PLWH with and without CM and those without HIV with and without CM.

03

Conditions studied

  • HIV
  • Depression
  • Cannabis Use Disorder
  • Stress
  • Pain
04

Who can participate

Ages eligible
18 Years to 68 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • good health as verified by screening examination
  • Able to read English and complete study evaluations and provide informed written and verbal consent. Additional criteria PLWH
  • -1 lab test positive
  • undetectable viral load
  • good ART adherence

Additional criteria by group:

PLWH +CM:

  • CB positive urine toxicology
  • meet criteria for CUD and MDD as assessed using SCID-I. HC
  • HIV-1 test negative
  • urine toxicology negative
  • no major medical and psychiatric diagnoses based on DSM-V.

PLWH Only:

  • HIV-1 test positive
  • urine toxicology negative
  • no major medical and psychiatric diagnoses based on DSM-V.

CM Only:

  • HIV-1 test negative
  • urine toxicology positive
  • meet DSM-5 criteria for CUD and MDD as assessed using SCID-I

Exclusion criteria

Exclusion Criteria:

  • meet primary, current moderate and severe criteria for other SUD including cocaine, alcohol, opiates, sedatives, nicotine
  • current use or past history of cocaine or opioid use disorder
  • history of any psychotic disorder
  • current diagnoses of bipolar disorder and PTSD
  • psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania)
  • significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology that would interfere with study participation
  • medications with known central effects on HPA axis and cytokines/immune function
  • women who are pregnant, nursing or those using hormonal that affect HPA axis cortisol responses.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    HIV-positive (PLWH+)

    Participants that are HIV-positive only will undergo 2 Within Subjects factors of Condition, Stress and No Stress (order of condition randomly assigned and counterbalanced)

    Other: Yale Pain Stress Task (YPST)

  • Experimental
    HIV-positive and complex morbidity (PLWH/CM+)

    Participants that are HIV-positive with complex morbidities will undergo 2 Within Subjects factors of Condition, Stress and No Stress (order of condition randomly assigned and counterbalanced)

    Other: Yale Pain Stress Task (YPST)

  • Experimental
    Healthy control (HC)

    Participants that are not HIV-positive and no complex morbidities will undergo 2 Within Subjects factors of Condition, Stress and No Stress (order of condition randomly assigned and counterbalanced)

    Other: Yale Pain Stress Task (YPST)

  • Experimental
    Control and complex morbidity (HC+CM)

    Participants that are not HIV-positive and have complex morbidities will undergo 2 Within Subjects factors of Condition, Stress and No Stress (order of condition randomly assigned and counterbalanced)

    Other: Yale Pain Stress Task (YPST)

Interventions

  • OtherYale Pain Stress Task (YPST)

    Individuals in the experimental cohort will be scheduled for 2 experimental sessions 1-3 days apart. The YPST stress experiment includes a stress and no-stress session (order randomly assigned, counter-balanced across subjects), and involves multiple (up to 3) unpredictable number of consecutive 3-minute trials of ice-bath (stress) or warm-bath (no stress) forearm immersion (stress) with subjective, physiologic endocrine and immune assessments repeated at specified time points.

06

What researchers measure

Primary outcomes

  1. Change in cortisol levels

    Mean change in cortisol levels (pg/ml) assessed using repeated blood sampling over 2 hour period on 2 separate days to extract plasma for cortisol measurement using standard RIA assay procedures.

    Time frame: day 1 and day 3

  2. Change in adrenocorticotropic hormone (ACTH) levels

    Mean change in pain stress assessed using repeated blood sampling over 2 hour period on 2 separate days to extract plasma for ACTH measurement using standard RIA assay procedures.

    Time frame: day 1 and day 3

  3. Change in pain stress

    Mean change in pain stress assessed using repeated sampling over 2 hour period on 2 separate days using 10-point visual analog scales (VAS) where 0 is not at all and 10 is the most pain being experienced.

    Time frame: day 1 and day 3

Secondary outcomes

  1. Mean behavioral pain tolerance

    Time in seconds that hand remains immersed in ice cold and warm water over 3 trials of 3 minutes each as a measure of behavioral pain tolerance

    Time frame: day 1 or day 3

  2. Mean Heart Rate

    Heart rate (bpm) assessed using repeated sampling over 2 hour period on 2 separate days using standard heart rate monitor.

    Time frame: day 1 and day 3

  3. Mean Blood pressure (systolic and diastolic)

    Blood pressure (mmHg), systolic and diastolic,assessed using repeated sampling over 2 hour period on 2 separate days using standard blood pressure monitor.

    Time frame: day 1 and day 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual de-identified data will be uploaded into National Institute of Mental Health Data Archive (NDA) data repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2030, 60 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 60 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 20, 2025
StartActual
Jan 16, 2025
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06784908
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jan 16, 2025
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Apr 27, 2026

Study contacts

Rachel Hart, MA
Contact
Rachel.hart@yale.edu
203-737-4791
Rajita Sinha, Ph.D.
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion